In this episode, Medicom’s correspondent covers 6 presentations from the annual meeting of the Heart Failure Association (HFA 2023), held in Prague, Czech Republic from 20-23 May.
The topics discussed are:
- Aficamten may lower symptom burden in non-obstructive hypertrophic cardiomyopathy
The open-label, dose-finding REDWOOD-HCM Cohort 4 study demonstrated that patients with non-obstructive hypertrophic cardiomyopathy achieve distinct symptom relief when treated with the myosin inhibitor aficamten. Moreover, angina symptom frequency was significantly reduced. - ENACT-HF: Standardised diuretic protocol improves natriuresis in acute heart failure
Following a natriuresis guided protocol in diuretic use led to a 64% increased natriuresis after 24 hours. In addition, duration of hospitalisation was 1 day shorter in the intervention group in the prospective ENACT-HF trial. - NUDGE-FLU: Repeated electronic nudges improve flu vaccination rates in patients with HF
Repeated electronic nudges and letters focusing on the cardiovascular benefits of flu vaccination are successful tools to motivate patients with heart failure (HF) to get vaccinated. The current pre-specified analysis of the NUDGE-FLU study also revealed alarmingly low vaccination rates in HF patients <65 years. - Copper chelating agent improves biomarkers and quality of life in HF patients
The TRACER-HF trial indicates that therapy with a copper chelator may have beneficial effects in heart failure patients and should be evaluated in further studies. In addition, the therapy did not affect blood pressure and heart rate. - Haemodynamic monitoring improves quality of life and lowers hospitalisations in HF patients
Remote pulmonary artery pressure monitoring met all primary and secondary endpoints in the MONITOR-HF trial. This was the first positive study of remote monitoring in European patients. - AI-based technology successful in SARS-CoV-2 symptoms screening
The language-based AI model Alexa performed similarly to a healthcare professional in SARS-CoV-2 symptoms screening in patients with heart failure (HF) and their caregivers in the VOICE-COVID-II trial. AI-based assistance could relieve healthcare systems, at least in simple tasks like symptom screening.
Enjoy listening!
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Coeliac Disease: “among the top 10 hard-to-diagnose common diseases” – an interview with Dr Cynthia Kelly Next Article
Key correlates of incident dementia identified in the MESA study »
« Coeliac Disease: “among the top 10 hard-to-diagnose common diseases” – an interview with Dr Cynthia Kelly Next Article
Key correlates of incident dementia identified in the MESA study »
Table of Contents: HFA 2023
Featured articles
Chronic Heart Failure — What You Need to Know
Sacubitril/valsartan reduces natriuretic peptides in HF patients with ejection fraction >40%
Clinically relevant reduction in HF hospitalisation due to haemodynamic monitoring
TRACER-HF: Trientine reduced biomarkers up to 8 weeks
Dapagliflozin improves LAVI, LV mass, and concentration of natriuretic peptides after 6 months
NUDGE-FLU: Repeated electronic nudges improve flu vaccination rates in patients with HF
Novel Therapeutics in Cardiomyopathy
Patisiran benefits maintained over 18 months in patients with transthyretin amyloidosis
Aficamten may lower symptom burden in non-obstructive hypertrophic cardiomyopathy
What is New in Acute Heart Failure?
Standardised diuretic protocol significantly increases natriuresis in acute HF
Low concentrations of VEGF-C: a negative prognostic factor
Prevention and Comorbid Conditions of Heart Failure
VOICE-COVID-II : Alexa successful in SARS-CoV-2 symptoms screening
HF patients with metabolic dysfunction at high risk to develop depressive symptoms
Best of the Posters
Frequent co-existence of atrial fibrillation and obstructive sleep apnoea in stroke patients
Protein-bound uremic toxins predict HF events and death in patients with CKD
Related Articles
October 27, 2022
Pooled analysis of DAPA-HF and DELIVER
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com